With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
*Based on Preferred Stock Price, Forty Seven does not have a stock symbol since it is currently private and is yet to have an IPO.
EquityZen does not have an affiliation with, formal relationship with, or endorsement from the companies featured above.
These profiles are based on publicly available information and are intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.
Have a question or need support? We're here to help! Send us a quick message and we'll get right back to you.
Thanks you for your message - we'll contact you shortly.